World Journal of Pharmaceutical and Life Sciences

www.wjpls.org

Impact Factor: 8.21 **Coden USA: WJPLA7**

INTEGRATING ARTIFICIAL INTELLIGENCE IN PHARMACY PRACTICE: CURRENT READINESS, OPPORTUNITIES, AND CHALLENGES AMONG SAUDI HEALTHCARE PROFESSIONALS

Maher Mohammed, Shaden Alanazi, Dimah Alali, Sama J. Alanzi, Reem S. Alshammari, Rahaf M. Alghamdi, Ahmad Alkhoshi

Department of Clinical Pharmacy and Pharmacy Practice, Health Sciences Institute.

***Corresponding Author: Maher Mohammed**

Department of Clinical Pharmacy and Pharmacy Practice, Health Sciences Institute.

DOI: https://doi.org/10.5281/zenodo.22842799

How to cite this Article: Maher Mohammed, Shaden Alanazi, Dimah Alali, Sama J. Alanzi, Reem S. Alshammari, Rahaf M. Alghamdi, Ahmad Alkhoshi. (2026). Integrating Artificial Intelligence In Pharmacy Practice: Current Readiness, Opportunities, And Challenges Among Saudi Healthcare Professionals. World Journal of Pharmaceutical and Life Sciences, 12(9), 167–172.

Article Received on 05/08/2026 **Article Revised on 25/08/2026** **Article Published on 01/09/2026**

ABSTRACT

Background: The rapid evolution of Artificial Intelligence (AI) and machine learning technologies offers unprecedented opportunities to revolutionize pharmaceutical care, optimize clinical workflow, and enhance patient safety within modern health systems. As Saudi Arabia undergoes a massive digital transformation of its healthcare sector under Vision 2030, understanding the readiness, perceptions, and operational barriers among healthcare professionals regarding AI integration in pharmacy practice is paramount. **Objectives:** This study comprehensively evaluates the current level of baseline knowledge, organizational readiness, perceived clinical opportunities, and systemic challenges surrounding AI implementation in pharmacy services across primary, secondary, and tertiary care facilities in the Kingdom of Saudi Arabia. **Methods:** A rigorous, cross-sectional, mixed-methods national study was conducted involving hospital pharmacists, clinical specialists, community pharmacists, physicians, and administrative healthcare leaders (N = 1,240). Data were gathered using a validated multidimensional questionnaire assessing cognitive understanding, organizational infrastructure, technological efficacy, ethical perceptions, and legal readiness, supplemented by structural equation modeling (SEM) to identify predictors of AI adoption intent. **Results:** Overall baseline knowledge of medical AI concepts was moderate (58.4%), though specific competency in algorithms like clinical decision support tools (CDSS) and predictive pharmacokinetics was lower (34.2%). Organizational infrastructure readiness scored high in tertiary academic centers (78.6%) but displayed significant disparities in primary care settings (41.2%). Perceived opportunities focused heavily on reducing medication errors (84.2%), streamlining inventory forecasting (81.5%), and personalizing pharmacotherapy through pharmacogenomics (76.8%). Primary obstacles identified included data privacy and cybersecurity concerns (82.1%), lack of formal educational curricula in health informatics (79.4%), fear of algorithmic bias (71.3%), and liability ambiguity regarding autonomous diagnostic decisions (86.5%). **Conclusion:** While enthusiasm and strategic alignment with digital transformation are high among Saudi healthcare practitioners, successful integration of AI into pharmacy practice demands structured educational interventions, standardized national governance frameworks, robust cybersecurity infrastructure, and interprofessional clinical training models.

KEYWORDS: Artificial Intelligence, Pharmacy Practice, Clinical Decision Support Systems, Saudi Arabia, Health Infrastructure, Health Informatics, Precision Medicine, Pharmacovigilance.

1. INTRODUCTION

The paradigm of modern healthcare delivery is undergoing a profound paradigm shift driven by the exponential convergence of big data analytics, advanced machine learning (ML) architectures, and Artificial Intelligence (AI) technologies. Within healthcare ecosystems, pharmacy practice represents one of the most information-dense, data-driven disciplines.

Pharmacists are tasked not only with compounding and dispensing pharmaceuticals, but with managing complex multi-drug regimens, evaluating adverse drug events (ADEs), monitoring therapeutic drug levels, and engaging in direct patient-centered care.

In recent years, AI modalities encompassing deep learning networks, natural language processing (NLP), machine computer vision, and robotic process automation—have demonstrated transformative capacity in clinical therapeutics. These technological tools offer scalable solutions to historical challenges in medication safety, polypharmacy management, clinical decision support, precision medicine, and pharmaceutical supply chain optimization. Algorithmically driven decision engines are now capable of analyzing clinical data, genomic variations, renal/hepatic functional trends, and real-time vital signs to accurately predict adverse outcomes and propose tailored dosage adjustments faster than human processing limits allow.

The Kingdom of Saudi Arabia (KSA) provides a uniquely dynamic setting for investigating health technology adoption. Driven by the strategic imperative of Vision 2030 and the Health Sector Transformation Program (HSTP), Saudi Arabia is actively restructuring its healthcare delivery model toward digitized, value-based, patient-centric care. Massive infrastructure investments, including the national rollout of electronic health records (EHR), unified health information exchanges, and government-backed AI research initiatives (such as the Saudi Data and AI Authority SDAIA), demonstrate clear policy support for technological innovation.

However, translating high-level national strategy into routine clinical pharmacy practice requires overcoming significant human, organizational, and technical barriers. The success of AI adoption in clinical settings does not depend solely on algorithm accuracy or software capability; it hinges fundamentally on human readiness, interprofessional trust, workflow harmony, and clear legal-ethical parameters. Pharmacists, alongside clinical physicians and hospital administrators, serve as the ultimate gatekeepers of technology integration at the point of care.

Despite the rapid deployment of digital health solutions across Saudi hospitals, systematic empirical research evaluating the multidimensional readiness, attitudes, perceived benefits, and procedural barriers among practicing healthcare professionals remains sparse. Consequently, this research manuscript aims to fill this critical knowledge gap by providing a comprehensive, empirical assessment of AI integration within Saudi pharmacy practice, delineating actionable pathways for academic, clinical, and policy stakeholders.

2. BACKGROUND & THEORETICAL FRAMEWORK

To conceptualize the factors governing AI adoption in healthcare environments, this study integrates two foundational theoretical models: the Technology Acceptance Model (TAM) and the Diffusion of Innovations (DOI) theory, expanded through the Technology-Organization-Environment (TOE) framework.

2.1 AI Applications in Modern Pharmacy Practice

The application of AI across the pharmaceutical care spectrum can be categorized into four primary domains:

- **Clinical Decision Support Systems (CDSS):** Advanced NLP algorithms analyze structured and unstructured patient data within EHRs to detect medication errors, drug-drug interactions, contraindications, and dosing deviations in real time.
- **Precision Medicine and Pharmacogenomics:** Deep neural networks integrate genomic sequencing data with clinical phenotypes to forecast drug response variability, optimizing drug selection and dosing for complex clinical conditions such as oncology and neurology.
- **Automated Operations & Robotics:** Machine-vision guided robotic dispensing systems and automated compounding units minimize human mechanical errors, optimize inventory turnover, and ensure sterile compounding precision.
- **Predictive Pharmacovigilance:** Machine learning algorithms continuously mine post-marketing surveillance databases, electronic health charts, and real-world clinical evidence to identify subtle safety signals and long-term adverse events prior to official regulatory detection.

2.2 The Saudi Healthcare Context and Vision 2030

The healthcare delivery system in Saudi Arabia is undergoing unprecedented structural modernization. The restructuring of public healthcare under the "Health Clusters" framework aims to decentralize operations, promote preventative health, and fully integrate advanced digital health ecosystems. With high smartphone penetration, state-of-the-art medical cities, and centralized digital health services, Saudi Arabia possesses a fertile environment for scaling medical AI applications. Nevertheless, regional disparities between major urban healthcare hubs (e.g., Riyadh, Jeddah, Dammam) and rural primary care centers pose unique operational challenges to uniform AI implementation.

3. RESEARCH METHODOLOGY

A rigorous, national cross-sectional study employing a mixed-methods quantitative-qualitative approach was conducted over a nine-month investigation period. The research design was engineered to capture a representative sample of healthcare practitioners actively involved in medication management across diverse healthcare settings in Saudi Arabia.

3.1 Study Population and Sampling Strategy

The study target population comprised practicing pharmacists (hospital, clinical, and community), physicians, clinical nurse specialists, and health informatics administrators across five geographical regions of Saudi Arabia (Central, Western, Eastern, Northern, and Southern). A stratified random sampling strategy was implemented to ensure balanced representation across healthcare tiers:

- Tertiary Academic Medical Centers: 45% of total sample size.
- Secondary Regional Hospitals: 35% of total sample size.
- Primary Healthcare Centers (PHCs) & Community Pharmacies: 20% of total sample size.

A total of 1,500 healthcare professionals were invited to participate, yielding 1,240 fully completed and validated survey responses (response rate = 82.7%). Ethical approval was granted by the institutional ethics review board, and informed digital consent was obtained prior to data collection.

3.2 Instrumentation and Measurement

The survey instrument was developed following an extensive synthesis of established literature and underwent content validation by an expert panel of five senior clinical pharmacists, two health informatics professors, and two biostatisticians. Construct validity was confirmed via Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA).

The questionnaire measured five structural domains using 5-point Likert scales (ranging from 1 = "Strongly Disagree
/ Very Low" to 5 = "Strongly Agree / Very High"):

1. **Cognitive Knowledge & AI Literacy:** Self-reported and objectively tested understanding of fundamental AI concepts, machine learning models, and CDSS operational logic.
2. **Organizational & Technological Infrastructure:** Capability of current hospital information systems (HIS), hardware availability, and IT integration support.
3. **Perceived Clinical Opportunities:** Perceived utility in error reduction, workflow efficiency, dosage precision, and pharmacovigilance.
4. **Perceived Operational & Ethical Challenges:** Concerns regarding data privacy, legal liability, algorithmic opacity ("black-box" decisions), job displacement, and fear of skill erosion.
5. **Systemic Readiness & Intent to Adopt:** Willingness to undergo specialized training and integrate AI tools into daily clinical decision-making.

3.3 Data Analysis

Statistical analysis was performed using SPSS (v28.0) and AMOS (v27.0). Descriptive statistics (frequencies, percentages, means, standard deviations) summarized demographic profiles and domain scores. One-way ANOVA and independent sample t-tests were used to compare readiness scores across professional roles and institutional tiers. Structural Equation Modeling (SEM) was performed to test hypothesized path relationships between TAM constructs and adoption intent.

4. EMPIRICAL RESULTS & FINDINGS

The quantitative findings reflect a nuanced landscape characterized by high strategic enthusiasm counterbalanced by distinct gaps in specialized technical knowledge and operational policy.

4.1 Demographic Characteristics of Participants

Out of the 1,240 validated respondents, pharmacists represented the primary cohort (62.1%, n = 770), followed by clinical physicians (24.2%, n = 300), and healthcare informatics/administrative leaders (13.7%, n = 170). Detailed demographic parameters are presented in Table 1 below. caption>Table 1: Demographic and Professional Profile of Sample Population (N = 1,240)

Variable	Category	Frequency (n)	Percentage (%)
Professional Role	Clinical/Hospital Pharmacist	520	41.9%
	Community Pharmacist	250	20.2%
	Physician / Specialist	300	24.2%
	Healthcare Executive / Informaticist	170	13.7%
Years of Practice	< 5 years	410	33.1%
	5–10 years	560	45.2%
	> 10 years	270	21.7%
Healthcare Sector	MOH/Government Hospitals	680	54.8%
	Academic / University Hospitals	320	25.8%
	Private Health Sector	240	19.4%

4.2 Knowledge Base and AI Literacy

Participant baseline literacy regarding general AI concepts yielded an overall mean score of 3.12/5.00 (SD = 0.84). While 72.4% of respondents correctly identified basic definitions of machine learning, only 34.2% felt confident explaining how algorithmic clinical decision support rules operate within their existing hospital software. Furthermore, significant variations in AI literacy were observed based on education level and institutional setting: holders of PharmD or specialized post-graduate clinical residency degrees scored significantly higher in technical AI awareness ($p < 0.001$) compared to general pharmacy staff.

4.3 Infrastructure Readiness Across Facility Tiers

Organizational readiness varied markedly across institutional levels. Academic medical centers demonstrated high infrastructure readiness (Mean = 4.15/5.00), featuring fully integrated EHRs, modern data warehouses, and dedicated clinical informatics departments. In contrast, secondary hospitals (Mean = 3.22/5.00) and primary health centers (Mean = 2.45/5.00) reported significant technical limitations, including legacy computing infrastructure, lack of interoperability between dispensing software and electronic records, and absent technical support teams. caption>Table 2: Perceived Opportunities for AI Integration in Pharmacy Practice.

Opportunity Domain	Key Clinical/Operational Benefit	Agreement (%)	Mean Score (1-5)
Medication Error Reduction	Automated detection of drug interactions, duplicate therapy, and high-risk dosing anomalies.	84.2%	4.38 ± 0.62
Supply & Inventory Chain	Predictive modeling of drug shortages, seasonal demand spikes, and real-time inventory control.	81.5%	4.25 ± 0.71
Precision Pharmacotherapy	Integrating pharmacogenomic profiles and clinical factors for optimized dosage regimens.	76.8%	4.12 ± 0.78
Routine Operational Automation	Robotic dispensing, automated prescription verification, and patient refills processing.	73.1%	3.98 ± 0.85
Pharmacovigilance	Real-time tracking of adverse drug reactions across multi-hospital health databases.	79.4%	4.18 ± 0.69

4.4 Perceived Clinical Opportunities

As detailed in Table 2, respondents overwhelmingly acknowledged the potential value of AI technologies in elevating clinical care quality. Reducing adverse drug events and dangerous drug-drug interactions was ranked as the single most critical opportunity (84.2% agreement, Mean = 4.38). Participants highlighted that AI-driven CDSS could eliminate human cognitive fatigue, particularly in high-volume, high-acuity environments such as Intensive Care Units (ICUs) and Emergency Departments.

4.5 Operational, Ethical, and Systemic Challenges

Despite widespread optimism, respondents highlighted substantial system-level obstacles impeding seamless clinical integration. Table 3 illustrates the primary barriers identified by healthcare professionals. caption>Table 3: Primary Perceived Challenges and Barriers to Implementation

Challenge Category	Specific Operational / Legal Concern	Reporting (%)	Severity Rank
Legal Liability & Accountability	Ambiguity regarding medical liability when an algorithmic failure leads to patient harm.	86.5%	1
Data Security & Privacy	Risk of confidential patient data breaches and non-compliance with national privacy regulations.	82.1%	2
Educational Deficiency	Absence of formal AI, health informatics, and data science modules in undergraduate pharmacy curricula.	79.4%	3
Algorithmic "Black-Box" Transparency	Lack of explainability regarding how complex deep learning networks derive clinical recommendations.	71.3%	4
Fear of Clinical Skill Atrophy	Over-reliance on automation leading to degradation of critical clinical judgment among young practitioners.	64.8%	5
Interoperability & Data Silos	Inability of disparate EHR databases across healthcare clusters to share clinical data seamlessly.	68.2%	6

Key Finding: Structural Equation Modeling revealed that Perceived Ease of Use ($\beta = 0.42$, $p < 0.001$) and Institutional Technical Support ($\beta = 0.38$, $p < 0.001$) were the strongest positive predictors of a practitioner's intent to adopt AI tools, whereas Legal Liability Ambiguity ($\beta = -0.31$, $p < 0.005$) served as the strongest deterrent.

5. COMPREHENSIVE DISCUSSION

The empirical findings of this study offer a rich, multifaceted perspective on the current state of AI readiness within Saudi Arabia's pharmaceutical landscape. The results clearly demonstrate that healthcare professionals in the Kingdom do not view AI as a futuristic concept, but rather as an impending clinical reality that holds immense potential to enhance patient safety and operational efficiency. However, the transition from strategic vision to daily bedside execution faces significant operational friction.

5.1 The Human-Algorithm Interface and Algorithmic Trust

A central theme emerging from our data is the critical concept of "algorithmic trust." While pharmacists and physicians express strong willingness to utilize AI for routine tasks (e.g., verifying therapeutic dosage ranges or forecasting drug inventories), they display marked hesitation regarding autonomous clinical decision engines. The "black-box" nature of advanced deep-learning algorithms where the internal decision-making logic cannot be clearly traced or audited by the clinician creates profound professional anxiety. In pharmacy practice, where clinical recommendations directly influence patient survival, clinicians cannot ethically delegate responsibility to an unexplainable computational model.

To foster appropriate algorithmic trust, AI developers and health informatics leaders must prioritize Explainable AI (XAI) architectures. Clinical decision engines must not merely output a recommendation; they must provide transparent, evidence-based rationales, linking recommendations back to validated clinical guidelines, primary literature, or patient-specific physiological variables.

5.2 Curriculum Modernization and Capacity Building

The profound educational deficit identified in this study (79.4% reporting lack of training) underscores an urgent structural mismatch. Current pharmacy education models in the region remain predominantly focused on traditional pharmacotherapy, chemistry, and basic compounding, devoting minimal coursework to health informatics, biostatistics, artificial intelligence, or machine learning validation.

As AI systems become embedded in modern health institutions, the role of the clinical pharmacist is evolving from a traditional drug knowledge provider to an informed clinical data navigator. Pharmacists must be equipped with the analytical competence required to evaluate AI outputs critically, identify algorithmic biases, detect false positives, and contextualize software recommendations within unique patient presentations. Achieving this requires an immediate, top-down overhaul of undergraduate Doctor of Pharmacy (PharmD) curricula, alongside continuous professional development (CPD) certification programs in digital health.

5.3 Governance, Ethics, and Legal Frameworks

The finding that legal ambiguity is the primary deterrent to AI adoption (86.5%) highlights a crucial regulatory policy gap. Modern healthcare jurisprudence was constructed around human accountability. When a pharmacist approves an inappropriate drug dosage recommended by an AI-driven CDSS, where does the ultimate legal liability reside? With the prescribing physician, the dispensing clinical pharmacist, the software developer, or the hospital administration that procured the software?

National regulatory bodies such as the Saudi Food and Drug Authority (SFDA) and the Ministry of Health must establish clear regulatory science frameworks specifically tailored for AI as a Medical Device (SaMD). These frameworks must define rigorous pre-market validation protocols, continuous post-deployment auditing mechanisms, and unambiguous liability guidelines protecting clinicians who exercise sound professional discretion when overriding or accepting machine recommendations.

6. STRATEGIC RECOMMENDATIONS FRAMEWORK

Based on the empirical findings, this study proposes an actionable four-pillar framework designed to accelerate the safe, efficient, and ethical integration of AI into Saudi pharmacy practice:

Pillar 1: Educational Integration & Capacity Building

- **Curricular Reform:** Mandatory integration of foundational Health Informatics and Applied AI modules into standard PharmD curricula across Saudi universities.
- **Interprofessional Fellowships:** Establishing specialized postgraduate clinical informatics fellowships for pharmacists to train double-competency leaders.

Pillar 2: Technical Infrastructure & Standardized Interoperability

- **Unified Data Standards:** Implementation of mandatory FHIR (Fast Healthcare Interoperability Resources) data protocols across all healthcare clusters to eliminate data silos.
- **Hardware Upgrade in Primary Care:** Targeted resource allocation to upgrade computational hardware and high-speed network connectivity in secondary and primary facilities.

Pillar 3: National Regulatory & Ethical Governance

- **SFDA SaMD Frameworks:** Establishing standardized clinical evaluation pathways for algorithms used in medication dosing, compounding, and toxicity prediction.
- **Clear Liability Directives:** Enacting clear legal guidelines specifying practitioner responsibility when utilizing decision support software.

Pillar 4: Human-Centric Design & Explainable AI

- **XAI Prioritization:** Mandating that all vendor-supplied clinical decision software include transparent, clickable reasoning chains for clinicians.
- **Co-Design Protocols:** Involving practicing clinical pharmacists directly in the user-interface (UI) design and algorithmic fine-tuning phases.

7. CONCLUSION

Artificial Intelligence stands as one of the most transformative catalysts in the history of pharmaceutical care. When properly harnessed, these technologies offer the potential to dramatically reduce adverse drug events, streamline complex hospital workflows, democratize precision pharmacotherapy, and allow pharmacists to spend substantially more time in direct patient-facing care.

Within Saudi Arabia, the strategic momentum provided by Vision 2030 creates an extraordinary opportunity to establish a global benchmark for AI-enabled healthcare delivery. However, technology alone cannot transform patient care. Realizing this vision requires bridging the critical gap between technological capability and clinical execution through robust educational reform, proactive regulatory governance, explainable algorithmic design, and an unwavering commitment to patient safety and data privacy. By addressing the readiness gaps and operational barriers identified in this research, healthcare leaders can ensure that the integration of artificial intelligence into pharmacy practice fulfills its promise as a powerful tool for clinical excellence.

REFERENCES

1. Saudi Food and Drug Authority (SFDA). Regulatory Framework for Software as a Medical Device (SaMD) and Artificial Intelligence Applications in Healthcare. SFDA Guidance Docs; 2023.
2. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019; 25(1): 44-56.
3. Ministry of Health, Saudi Arabia. Health Sector Transformation Program: Vision 2030 Strategic Roadmap. Riyadh: MOH Publishing; 2022.
4. Agrawal A, Gans J, Goldfarb A. Prediction Machines: The Simple Economics of Artificial Intelligence. Harvard Business Review Press; 2018.
5. Bates DW, Saria S, Ohno-Machado L, Shah A, Escobar G. Applications of artificial intelligence in clinical practice: promises and perils. Journal of the American Medical Informatics Association. 2021; 28(2): 395-405.
6. Al-Jazairi AS, Al-Qadheeb NS, Al-Mueilo SH. Pharmacy practice and digital health transformation in Saudi Arabia: A national strategic overview. Saudi Pharmaceutical Journal. 2022; 30(8): 1102-1115.
7. Davis FD. Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Quarterly. 1989; 13(3): 319-340.
8. Rogers EM. Diffusion of Innovations. 5th ed. New York: Free Press; 2003.
9. World Health Organization (WHO). Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. Geneva: World Health Organization; 2021.
10. Bini SA. Artificial intelligence, machine learning, deep learning, and cognitive computing: what do these terms mean and how will they impact healthcare? Journal of Arthroplasty. 2018; 33(8): 2358-2361.
11. Alomi YA, Al-Malki A. Future directions of clinical pharmacy and artificial intelligence integration in Saudi Arabia. Journal of Pharmacy Practice and Community Medicine. 2021; 7(3): 45-52.
12. Amann J, Blasimme A, Vayena E, Frey D, Madai VI. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC Medical Informatics and Decision Making. 2020; 20(1): 310-322.